Elisabeth L. Vikse
Oslo, Norway
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 9 publications
Assessment of human immunity to A/H3N2 influenza subclade K during 2025 emergence.
Journal: EBioMedicine
Published: March 16, 2026
Long-lasting cross-reactive and polyfunctional SARS-CoV-2 T cell responses in seniors are maintained after repeated vaccination and infections.
Journal: Vaccine
Published: December 16, 2025
SARS-CoV-2 Infection With Alpha B.1.1.7 Virus Induced Higher Antibody Responses Than Earlier Non-VOC Variants During the First Waves of the COVID-19 Pandemic in Norway.
Journal: APMIS : acta pathologica, microbiologica, et immunologica Scandinavica
Published: March 14, 2025
Low Levels of Neutralizing Antibodies Against SARS-CoV-2 KP.3.1.1 and XEC in Serum From Seniors in May 2024.
Journal: Influenza and other respiratory viruses
Published: December 20, 2024
Characterization of the SARS-CoV-2 antibody landscape in Norway in the late summer of 2022: high seroprevalence in all age groups with patterns of primary Omicron infection in children and hybrid immunity in adults.
Journal: BMC infectious diseases
Published: October 10, 2023
A pan-SARS-CoV-2-specific soluble angiotensin-converting enzyme 2-albumin fusion engineered for enhanced plasma half-life and needle-free mucosal delivery.
Journal: PNAS nexus
Published: September 21, 2023
Poor neutralizing antibody responses against SARS-CoV-2 Omicron BQ.1.1 and XBB in Norway in October 2022.
Journal: Influenza and other respiratory viruses
Published: January 10, 2023
Antigen Targeting to Human HLA Class II Molecules Increases Efficacy of DNA Vaccination.
Journal: Journal of immunology (Baltimore, Md. : 1950)
Published: May 23, 2016
Vaccine molecules targeting Xcr1 on cross-presenting DCs induce protective CD8+ T-cell responses against influenza virus.
Journal: European journal of immunology
Published: July 30, 2014
Showing 1-9 of 9
Last Updated: 09/26/2026